This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
by Zacks Equity Research
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's overall clinical program data.
JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change
biotechs medical pharmaceuticals
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
by Zacks Equity Research
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change CMPXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
by Zacks Equity Research
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
BMRNNegative Net Change VRTXNegative Net Change CSTLPositive Net Change HRMYNegative Net Change
biotechs
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
by Zacks Equity Research
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
BMRNNegative Net Change JAZZNegative Net Change AXSMNegative Net Change HRMYNegative Net Change
biotechs
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
by Zacks Equity Research
Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States.
ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
4 Healthcare Stocks Poised to Crush Q4 Earnings Estimates
by Kaibalya Pravo Dey
Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.
AMGNPositive Net Change HUMNegative Net Change CORPositive Net Change ARDTNegative Net Change
biotechs earnings insurance medical pharmaceuticals
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
by Zacks Equity Research
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
REGNPositive Net Change RHHBYPositive Net Change PRTAPositive Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
SNYPositive Net Change JNJPositive Net Change TEVAPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
by Zacks Equity Research
Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.
BIIBNegative Net Change CYTKPositive Net Change AKROPositive Net Change
biotechnology biotechs
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs earnings-preview pharmaceuticals
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
by Zacks Equity Research
SAGE and AKRO are up this week on regulatory and pipeline updates.
BIIBNegative Net Change CYTKPositive Net Change AKROPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
by Zacks Equity Research
The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.
BMRNNegative Net Change ALLOPositive Net Change CSTLPositive Net Change HRMYNegative Net Change
biotechs
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
by Zacks Equity Research
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.
NVOPositive Net Change MDGLNegative Net Change AKROPositive Net Change ETNBNegative Net Change
biotechnology biotechs medical pharmaceuticals
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
by Zacks Equity Research
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change
biotechs medical pharmaceuticals
Novartis to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.
NVSPositive Net Change AMGNPositive Net Change EXELNegative Net Change SRPTNegative Net Change
biotechs medical pharmaceuticals
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
by Zacks Equity Research
Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.
BIIBNegative Net Change CSTLPositive Net Change HRMYNegative Net Change
biotechs
How to Play NVO Stock After New Drug's Success in Obesity Study
by Ahan Chakraborty
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
by Zacks Equity Research
The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.
AZNPositive Net Change ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
by Zacks Equity Research
A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.
PFENegative Net Change CTMXNegative Net Change CSTLPositive Net Change ERASNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
by Sundeep Ganoria
Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings-preview medical pharmaceuticals
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
by Zacks Equity Research
EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study.
BMYNegative Net Change MRKPositive Net Change EXELNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
by Zacks Equity Research
Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to placebo in an obesity study.
ALNYPositive Net Change BMRNNegative Net Change NVOPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
by Zacks Equity Research
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi every four weeks prolongs biomarker benefits.
BIIBNegative Net Change LLYPositive Net Change PRTAPositive Net Change
biotechs medical pharmaceuticals vaccines
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
by Kinjel Shah
J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.
SNYPositive Net Change AZNPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs pharmaceuticals
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
RDYNegative Net Change ALNYPositive Net Change GILDNegative Net Change CHRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals